GlaxoSmithKline (GSK) United Kingdom (External organisation)

  • De Silva, I. (Inventor)
  • Armin Sepp (Inventor)
  • Allart Adriaan Stoop (Inventor)

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Patents › Patent

Description

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.

US20150210767A1 - United States
Application US14/682,176 events
2009-10-27 Priority to US25523509P
2010-10-25 Priority to PCT/EP2010/066046
2012-04-27 Priority to US201213504525A
2012-12-06 First worldwide family litigation filed
2015-04-09 Application filed by Glaxo Group Ltd
2015-04-09 Priority to US14/682,176
2015-05-21 Assigned to GLAXO GROUP LIMITED
2015-07-30 Publication of US20150210767A1
Period31 Jul 2015
Held atGlaxoSmithKline (GSK) United Kingdom, United Kingdom
Degree of RecognitionInternational

Documents & Links